Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Texas Oncology Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01500161
- Locations
- 🇺🇸
Texas Oncology, Amarillo, Texas, United States
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT01476839
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01471067
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 63
- Registration Number
- NCT01453088
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT01421173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 205
- Registration Number
- NCT01413178
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Reduced Intensity Double Umbilical Cord Blood Transplantation
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT01408563
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Hospital Sant Joan de Deu
- Target Recruit Count
- 5
- Registration Number
- NCT01393769
- Locations
- 🇪🇸
Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Cord Blood Transplantation for Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 1
- Registration Number
- NCT01359254
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
- Conditions
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 8
- Registration Number
- NCT01350258
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.